

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
032026-0700SERIAL NO.
10/036,819

INFORMATION DISCLOSURE CITATION

APPLICANT

Hayes et al.

FILING DATE

12/21/2001

GROUP ART UNIT

1616

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
SCB		5,446,035	August 29, 1995	Neef et al.	514	167	

RECEIVED

APR 17 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

Sabiha Qaz

DATE CONSIDERED

7/25/03

- EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

BEST AVAILABLE COPY

APR 22 2003

Page 1 of 1

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
032026-0700SERIAL NO.
10/036,819

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT

Hayes et al.

FILING DATE

12/21/2001

GROUP ART UNIT

1616

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

RECEIVED

APR 25 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Barrat et al. (DN 136:339213, CAPLUS, abstract of J. of Experimental Medicine (2002), 195(5), 603-616).

Penna et al. (DN 132:292680, CAPLUS, abstract of J. of Immunology (2000), 164(5), 2405-2411).

Dam et al. (DN 132:146376, CAPLUS, abstract of J. of Investigative Dermatology (1999), 113(6), 1082-1089).

EXAMINER

SABHA QAZI

DATE CONSIDERED

7/25/03

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

BEST AVAILABLE COPY

Form PTO-1449
(MODIFIED)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
032026-0700SERIAL NO.
10/036,819

APPLICANT

Hayes et al.

#6

FILING DATE

12/21/2001

GROUP ART UNIT

1616

INFORMATION DISCLOSURE CITATION

APR 21 2003

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Bemiss, C. J. et al., "Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system," *Archives of Biochemistry and Biophysics*, **402** (2002), pp. 249-254; published by Elsevier Science (USA).

Bickston, S.J. et al., "Recombinant Interleukin 10 for the Treatment of Active Crohn's Disease: Lessons in Biologic Therapy," *Gastroenterology*, **119** (6) (2000), pp. 1781-1783; published by American Gastroenterological Association (USA).

Cantorna, M. T. et al., "1,25-Dihydroxycholecalciferol Prevents and Ameliorates Symptoms of Experimental Murine Inflammatory Bowel Disease," *J. Nutr.*, **130** (2000), pp. 2648-2652; published by American Society for Nutritional Sciences (USA).

Colombel, J-F. et al., "Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease," *Gut*, **49** (2001) pp. 42-46; published by British Medical Association (United Kingdom).

Cornillie, F. et al., "Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease," *Aliment Pharmacol Ther.*, **15** (2001), pp. 463-473; published by Blackwell Science Ltd.

EXAMINER

Sabihah Qaz

DATE CONSIDERED

7/25/03

- * EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 032026-0700	SERIAL NO. 10/036,819
INFORMATION DISCLOSURE CITATION (use several sheets if necessary)		APPLICANT Hayes et al.	
		FILING DATE 12/21/2001	GROUP ART UNIT #6 1616
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Fedorak, R. N. et al., "Recombinant Human Interleukin 10 in the Treatment of Patients with Mild to Moderately Active Crohn's Disease," <i>Gastroenterology</i> , 119 (2000), pp. 1473-1482; published by American Gastroenterological Association (USA).	
		Fedorak, R. N. et al., "Human Recombinant Interleukin-10 is Safe and Well Tolerated But Does Not Induce Remission in Steroid Dependent Crohn's Disease," <i>Gastroenterology</i> , 120 (Supp. 1) (2001), p. A-127; published by W. B. Saunders (Philadelphia, USA).	
		Hanauer, S. B. et al., "Evolving Treatment Strategies for Inflammatory Bowel Disease," <i>Annu. Rev. Med.</i> , 52 (2001), pp. 299-318; published by Annual Reviews.	
		Kam, L. Y. et al., "TNF- α antagonists for the treatment of Crohn's disease," <i>Exp. Opin. Pharmacother.</i> , 1 (4) (2000), pp. 615-622; published by Ashley Publications Ltd.	
		Puchner, Thomas C. et al., "Successful Desensitization and Therapeutic Use of Infliximab in Adult and Pediatric Crohn's Disease Patients with Prior Anaphylactic Reaction," <i>Inflamm. Bowel Dis.</i> , 7 (1) (2001), pp. 34-37; published by Crohn's & Colitis Foundation of America, Inc. (USA).	
		Ricart, E. et al., "Infliximab for Crohn's Disease in Clinical Practice at the Mayo Clinic: The First 100 Patients," <i>Am. J. of Gastroenterology</i> , 96 (3) (2001), pp. 722-729; published by Am. Coll. of Gasstroenterology (USA).	
		Sandborn, W. J. et al., "An Engineered Human Antibody to TNF (CDP571) for Active Crohn's Disease: A Randomized Double-Blind Placebo-Controlled Trial," <i>Gastroenterology</i> , 120 (2001), pp. 1330-1338; published by American Gastroenterological Association (USA).	
		Sandborn, W. J. et al., "Etanercept for Active Crohn's Disease: A Randomized, Double-Blind, Placebo-Controlled Trial," <i>Gastroenterology</i> , 121 (5) (2001), pp. 1088-1094; published by American Gastroenterological Association (USA).	
		Sands, B. E. et al., "Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study," <i>Inflamm. Bowel Dis.</i> , 7 (2) (2001), pp. 83-88; published by Crohn's & Colitis Foundation of America, Inc. (USA).	
		Schreiber, S. et al., "Safety and Efficacy of Recombinant Human Interleukin 10 in Chronic Active Crohn's Disease," <i>Gastroenterology</i> , 119 (6) (2000), pp. 1461-1472; published by American Gastroenterological Association (USA).	
		Schreiber, S. et al., "Immunoregulatory Role of Interleukin 10 in Patients With Inflammatory Bowel Disease," <i>Gastroenterology</i> , 108 (5) (1995), pp. 1434-1444; published by American Gastroenterological Association (USA).	
		Stio, M. et al., "Suppressive effect of 1,25-dihydroxyvitamin D ₃ and its analogues EB 1089 and KH 1060 on T lymphocyte proliferation in active ulcerative colitis," <i>Biochemical Pharmacology</i> , 61 (2001), pp. 365-371; published by Elsevier Science Inc.	
		Targan, S. R., "Biology of inflammation in Crohn's disease: Mechanisms of action of anti-TNF- α therapy," <i>Can. J. Gastroenterology</i> , 14 (Suppl. C) (2000), pp. 13C-16C.	

Form PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 032026-0700	SERIAL NO. 10/036,819
INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		APPLICANT Hayes et al. #6	
		FILING DATE 12/21/2001	GROUP ART UNIT 1616
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
RECEIVED APR 24 2003 TECH CENTER 1600/2900	van Berge Henegouwen, G. P., ["Consensus for infliximab treatment of patients with Crohn's disease"], <i>Ned Tijdschr. Geneesk.</i> , 144 (38) (2000), pp. 1844-1845 (Netherlands). English Abstract is provided on page 1845 of the reference.		
	van Deventer, S. J. et al., "Multiple Doses of Intravenous Interleukin 10 in Steroid-Refractory Crohn's Disease," <i>Gastroenterology</i> , 113 (2) (1997), pp. 383-389; published by American Gastroenterological Association (USA).		
	Harries, A.D. et al., "Vitamin D status in Crohn's disease: association with nutrition and disease activity," <i>Gut</i> , 26 (1985), pp. 1197-1203.		
	Issenman, R. M., "Bone Mineral Metabolism in Pediatric Inflammatory Bowel Disease," <i>Inflamm. Bowel Dis.</i> , 5 (3) (1999), pp. 192-199; published by Crohn's & Colitis Foundation of America, Inc. (USA).		
	Jahnsen, J. et al., "Vitamin D Status, Parathyroid Hormone and Bone Mineral Density in Patients with Inflammatory Bowel Disease," <i>Scand. J. Gastroenterol.</i> , 37 (2002), pp. 192-199; published by Taylor & Francis.		
	Kirchgatterer, A. et al., "Examination, Prevention and Treatment of Osteoporosis in Patients with Inflammatory Bowel Disease: Recommendations and Reality," <i>Acta Medica Austriaca</i> , 29 (2002), pp. 120-123; U.S. Copyright Clearance Center Code Statement: 0303-8173/2002/2904-0120.		
	Lamb, E. J. et al., "Metabolic bone disease is present at diagnosis in patients with inflammatory bowel disease," <i>Aliment Pharmacol. Ther.</i> , 16 (2002), pp. 1895-1902; published by Blackwell Science Ltd.		
	Scharla, S. H. et al., "Bone mineral density and calcium regulating hormones in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis)," <i>Exp. Clin. Endocrinol.</i> , 102 (1994), pp. 44-49; published by Johann Ambrosius Barth.		
	Schulte, C. et al., "Reduced Bone Mineral Density and Unbalanced Bone Metabolism in Patients with Inflammatory Bowel Disease," <i>Inflamm. Bowel Dis.</i> , 4 (4) (1998), pp. 268-275; published by Crohn's & Colitis Foundation of America, Inc. (USA).		
	Silvennoinen, J., "Relationships between vitamin D, parathyroid hormone and bone mineral density in inflammatory bowel disease," <i>J. Intern. Med.</i> , 239 (2) (1996), pp. 131-137; published by Blackwell Science Ltd.		
Sonnenberg, A. et al., "25-Hydroxycholecalciferol Serum Levels in Patients with Crohn's Disease," <i>Acta Hepato-Gastroenterol.</i> , 24 (1977), pp. 293-295; published by Georg Thieme Verlag Stuttgart (Germany).			
Vogelsang, H. et al., "Bone Disease in Vitamin D-Deficient Patients with Crohn's Disease," <i>Digestive Diseases and Sciences</i> , 34 (7) (1989), pp. 1094-1099; published by Plenum Publishing Corporation (USA).			
Vogelsang, H. et al., "25-Hydroxyvitamin D. absorption in patients with Crohn's disease and with pancreatic insufficiency," <i>Wien Klin Wochenschr.</i> , 109 (17) (1997), pp. 678-682; published by Springer-Verlag (Austria).			